22 stories found
Multiple executives from various companies, including Tempus AI, Snowflake, and Crowdstrike, have engaged in significant stock transactions, with some selling millions in shares while others made purchases.
Halozyme has announced a deal with Incyte to utilize its Enhanze technology for a candidate targeting neoplasms.
Coherus BioSciences reported non-GAAP EPS of -$0.25, beating estimates, but missed revenue targets, while Halozyme Therapeutics exceeded expectations with non-GAAP EPS of $1.60 and revenue of $376.71 million.
Halozyme Therapeutics (HALO) is being highlighted as one of the most undervalued biotech stocks currently available for purchase.
Halozyme has announced the appointment of David Ramsay as its interim Chief Financial Officer, effective immediately.
Several companies, including HF Sinclair, VNET, Halozyme, Palo Alto, SolarEdge, TeraWulf, Applied Digital, USA Rare Earth, and Flagstar, saw their stock prices drop due to reasons ranging from CEO leave and earnings concerns to profit-taking and share disposals.
Halozyme has outlined a revenue target of $1.71 billion to $1.81 billion by 2026, driven by the expansion of its pipeline with new subcutaneous technologies.
Halozyme Therapeutics is preparing to announce its Q4 2025 earnings, drawing attention from investors keen on its financial performance and projections.
Halozyme has raised its 2026 revenue outlook to $1.835B-$1.91B, projecting non-GAAP EPS of $8.65-$9.00. Meanwhile, Bob's Discount Furniture reported Q2 revenue growth, with GAAP EPS of $0.20 and revenue of $619.6M.
Halozyme Therapeutics (HALO) has announced a new global collaboration and license agreement with GSK.
H.C. Wainwright has expressed a bullish sentiment regarding Halozyme Therapeutics, Inc. (HALO), particularly concerning its commercial revenue outlook.
Vertex Pharmaceuticals has entered into a partnership with Halozyme Therapeutics to utilize its Hypercon drug delivery technology, aiming to enhance pharmaceutical administration.
Investors are evaluating whether Halozyme Therapeutics (HALO) is a good investment opportunity following its recent earnings report.
Halozyme's stock fell following a fourth-quarter earnings miss, though the company reiterated its guidance for 2026.
Halozyme has published the transcript of its fourth-quarter 2025 earnings call.
Halozyme's stock shares are approaching all-time highs, a performance driven by the company's strategic partnerships and consistent earnings growth.
Halozyme Therapeutics has outlined projections for its ENHANZE royalties to exceed $1 billion by 2026 and announced a new $1 billion share buyback program.
Halozyme Therapeutics (HALO) has received a 'Buy' rating, driven by expectations of strong royalty growth.
Halozyme Therapeutics has announced the appointment of an interim Chief Financial Officer as the company continues to pursue its growth strategies.
An analysis presents a 'bull case theory' for Halozyme Therapeutics, Inc. (HALO) stock, suggesting potential for growth.
Halozyme Therapeutics, Inc. has released a summary of its fourth-quarter 2025 earnings call, detailing its financial performance.
Halozyme Therapeutics reported a non-GAAP EPS of -$0.24, missing estimates, but its revenue of $451M surpassed expectations.